重组人Sumo 1蛋白(ab3801)
Key features and details
- Expression system: Escherichia coli
- Active: Yes
- Suitable for: Functional Studies
描述
-
产品名称
重组人Sumo 1蛋白
参阅全部 Sumo 1 蛋白酶 -
生物活性
The final fraction of enzyme contains a single polypeptide band of 11 kDa. -
表达系统
Escherichia coli -
蛋白长度
Full length protein -
无动物成分
No -
性质
Recombinant -
-
种属
Human -
预测分子量
11 kDa
-
相关产品
-
Related Products
技术指标
Our Abpromise guarantee covers the use of ab3801 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
应用
Functional Studies
-
形式
Liquid -
补充说明
This product can be used as part of an assay for sumoylation activity. Human Aos 1 + Uba 2 (ab3804), Ubc 9 (ab3803) and Sumo 1 (ab3801) can be used to promote in vitro sumoylation of a sumoylation marker (human Topoisomerase I protein fragment) (ab3828). The reaction products can be detected using our Sumo 1 (ab3819 and ab3824) and Topoisomerase I (ab3825) antibodies. Sumoylation assays are carried out in a final volume of 20µl in reaction conditions (20 mM Hepes pH 7.5, 5mM MgCl2, 2mM ATP). Sumoylation Protocol: 1. Prepare a suitable purified substrate protein. (For the control, use 2µl Topoisomerase I marker for each reaction). 2. In each reaction, add 4µl E2 to substrate first, then 2µl Sumo 1, 2µl 10x reaction buffer, 2µl E1. Finally, add H2O to bring up to 20µl. We would recommend adding fresh 2mM ATP to be sure that sufficient energy is supplied. 3. The best reaction concentration of proteins is as following: Aos 1 + Uba 2: 7.5µg/ml. Ubc 9: 50µg/ml. SUMO 1: 50µg/ml. For the control assay we recommend running the assay at 37ºC for 30-60 minutes. 4. Detect the reaction products by Western blot using a suitable antibody. For the control reaction use 1/1000 dilution of the supplied Topoisomerase I antibody. Four sumoylated bands should be seen on the gel for the control reaction. This assay has been shown to work with crude extracts. Be aware that Uba 2 contains his-rich regions which might cross-react with antibodies against the 6x-His epitope tag. During western analysis with anti-6x-His antibodies, Uba 2 at 80 kDa might be shown.
The final fraction of enzyme contains a single polypeptide band of 11 kDa.
-
Concentration information loading...
制备和贮存
-
稳定性和存储
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
pH: 7.50
Preservative: 0.68% Imidazole
Constituents: 0.0087% PMSF, 0.0154% DTT, 0.158% Tris HCl, 10% Glycerol, 0.58% Sodium chlorideThis product is an active protein and may elicit a biological response in vivo, handle with caution.
常规信息
-
别名
- DAP1
- GAP modifying protein 1
- GAP-modifying protein 1
see all -
功能
Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. -
疾病相关
Defects in SUMO1 are the cause of non-syndromic orofacial cleft type 10 (OFC10) [MIM:613705]; also called non-syndromic cleft lip with or without cleft palate 10. OFC10 is a birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum. Note=A chromosomal aberation involving SUMO1 is the cause of OFC10. Translocation t(2;8)(q33.1;q24.3). The breakpoint occurred in the SUMO1 gene and resulted in haploinsufficiency confirmed by protein assays. -
序列相似性
Belongs to the ubiquitin family. SUMO subfamily.
Contains 1 ubiquitin-like domain. -
翻译后修饰
Cleavage of precursor form by SENP1 or SENP2 is necessary for function.
Polymeric SUMO1 chains undergo polyubiquitination by RNF4. -
细胞定位
Nucleus membrane. Nucleus speckle. Cytoplasm. Recruited by BCL11A into the nuclear body. - Information by UniProt
图片
-
SDS-PAGE - Recombinant human Sumo 1 protein (ab3801)
Left Lane: Topo I protein (Topo I fragment: ab3828)
Middle Lane: Sumo 1 sumoylated Topo I (Sumo 1: ab3801; Topo I fragment: ab3828; EI: ab3804; EII: ab3803; Buffer: ab3827)
Right Lane: Sumo 3 sumoylated Topo I (Sumo 3: ab3802; Topo I fragment: ab3828; EI: ab3804; EII: ab3803; Buffer: ab3827)
Note: Topo I is S35-Met labeled.
-
SDS-PAGE - Recombinant human Sumo 1 protein (ab3801)
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (1)
ab3801 被引用在 1 文献中.
- Zhou LJ et al. The SUMO E3 Ligase MdSIZ1 Targets MdbHLH104 to Regulate Plasma Membrane H+-ATPase Activity and Iron Homeostasis. Plant Physiol 179:88-106 (2019). PubMed: 30333149
